Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PABPC1 | P11940 | 1/20 | 0.49 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CTSS | P25774 | 3/20 | 0.43 |
| ▸ | CTSK | P43235 | 2/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | ACE | P12821 | 1/20 | 0.41 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29529271 | 0.98 | PABPC1 (0.48) | PABPC1MDM2HDAC8KDM4EMAPT | |
| SCHEMBL21639290 | 0.94 | MDM2 (0.52) | PABPC1MDM2HDAC8CTSSCTSK | |
| SCHEMBL21639288 | 0.94 | MDM2 (0.52) | PABPC1MDM2HDAC8CTSSCTSK | |
| SCHEMBL21639175 | 0.92 | MDM2 (0.51) | PABPC1MDM2HDAC8CTSSCTSK | |
| SCHEMBL21639174 | 0.92 | MDM2 (0.51) | PABPC1MDM2HDAC8CTSSCTSK | |
| SCHEMBL29539925 | 0.85 | KLK5 (0.46) | MAPTTDP1CTSSCTSKCTSL | |
| SCHEMBL17196273 | 0.85 | KLK5 (0.46) | MAPTTDP1CTSSCTSKCTSL | |
| SCHEMBL20646383 | 0.85 | KLK5 (0.46) | MAPTTDP1CTSSCTSKCTSL | |
| SCHEMBL31478692 | 0.85 | KLK5 (0.46) | MAPTTDP1CTSSCTSKCTSL | |
| SCHEMBL15691997 | 0.85 | NAMPT (0.49) | MDM2KDM4EMAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3604326-B1 | PEPTIDE COMPOUND AND METHOD FOR PRODUCING SAME, COMPOSITION FOR SCREENING USE, AND METHOD FOR SELECTING PEPTIDE COMPOUND | FUJIFILM CORP (JP) | 2026-01-07 | — | — | EP | disclosed |
| US-11319347-B2 | Peptide compound and method for producing same, composition for screening use, and method for selecting peptide compound | FUJIFILM CORPORATION (JP) | 2022-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11319347-B2 | Peptide compound and method for producing same, composition for screening use, and method for selecting peptide compound | VIP, NPPA, NGLY1 | PABPC1 1638/4885MDM2 4758/4885HDAC8 4140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.